VKTX Viking Therapeutics Inc

$40.03

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/16/2025

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.

Website: https://www.vikingtherapeutics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1607678
Address
12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, US
Valuation
Market Cap
$2.69B
P/E Ratio
nan
PEG Ratio
-0.03
Price to Book
3.05
Performance
EPS
$-1.01
Dividend Yield
—
Profit Margin
0.00%
ROE
-17.90%
Technicals
50D MA
$27.47
200D MA
$47.72
52W High
$81.86
52W Low
$18.92
Fundamentals
Shares Outstanding
112M
Target Price
$95.44
Beta
0.83

VKTX EPS Estimates vs Actual

● Estimated
● Actual

VKTX News & Sentiment

Aug 16, 2025 • Motley Fool NEUTRAL
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath.
Aug 15, 2025 • Zacks Commentary NEUTRAL
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.
Aug 13, 2025 • Benzinga NEUTRAL
Why Is Viking Therapeutics Stock Gaining Wednesday? - Viking Therapeutics ( NASDAQ:VKTX )
William Blair expects Viking's VENTURE-Oral trial to show nearly 7% placebo-adjusted weight loss. Eli Lilly's trial setback could give Viking an edge in the obesity treatment market. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
Aug 13, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Aug 13, 2025 • Motley Fool SOMEWHAT-BULLISH
The 3 Things That Matter for Viking Therapeutics Now
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
Aug 12, 2025 • Motley Fool BULLISH
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
The biopharmaceutical company has an exciting lead compound in development.
Sentiment Snapshot

Average Sentiment Score:

0.074
50 articles with scored sentiment

Overall Sentiment:

Neutral

VKTX Reported Earnings

Apr 22, 2025
Mar 31, 2025 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.41
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -31.7%
Feb 05, 2025
Dec 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: -14.3%
Oct 23, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 12.0%
Jul 24, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: 25.9%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 7.1%
Feb 07, 2024
Dec 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: 0.0%
Oct 25, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.22
  • Whisper: —
  • Surprise %: -4.5%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.19
  • Whisper: —
  • Surprise %: 0.0%
Apr 26, 2023
Mar 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: -4.2%

Financials